Attovia Therapeutics

Attovia Therapeutics develops a pipeline of biotherapeutics for immune-mediated diseases, harnessing its proprietary ATTOBODY platform to create multi-specific biologics with biparatopic target engagement. ATTOBODIES deliver ultra-high affinity and best-in-class potency while offering flexible engineering and tunable half-life for potentially quarterly dosing schedules. The high-throughput, evolution-based discovery process accelerates development, enhances diversity, and de-risks candidates, positioning Attovia as a next-generation modality in the biopharma landscape.